Department of Biomedical Sciences and The Danish National Foundation Research Center for Heart Arrhythmia, University of Copenhagen, Copenhagen, Denmark.
Trends Cardiovasc Med. 2010 Jan;20(1):8-12. doi: 10.1016/j.tcm.2010.02.012.
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
最近的实验数据表明，胰高血糖素样肽 1（GLP-1）及其类似物除了具有经典的血糖调节作用外，还对心血管系统有直接作用。这些直接作用可能具有心脏保护、增强收缩力和血管舒张作用。一些初步的临床试验似乎支持在左心室功能减弱的患者中给予 GLP-1 后改善机械功能。基于动物研究，减少缺血再灌注心肌的致命损伤似乎是一个特别有前途的前景，有待在临床环境中进行测试。
